Sudeep Pharma Ltd
Sudeep Pharma Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY '26 growth expected at approximately 26%, sustained for the full year. Sudeep Pharma expects to sustain the 26% growth achieved in H1 FY26 for the full year FY26 and beyond, driven by normalization of U.S.
From Sudeep Pharma Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '26 growth expected at approximately 26%, sustained for the full year.
- Significant growth anticipated in Q3 FY '26, especially in the US market, post-tariff clarity.
- NSS acquisition to drive European expansion with a focus on PAN-Europe growth; infant nutrition (70-75% of NSS revenue) is a key area.
- NSS capacity utilization currently ~35%, with plans to scale volumes notably by FY '27.
- New Greenfield facility (51,200 metric tons capacity) expected commissioning Q4 FY '26; first meaningful production from this site expected in H2 FY '27 and predominantly FY '28.
- Current overall manufacturing utilization near 50%, expected to increase with new capacity and approvals over next 2-3 years.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Sudeep Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Acquired a 20-acre land in Dahej for new manufacturing facility.
- Phase one capex for Dahej site: ~INR 220 crores (includes land and development) for 25,000 tons capacity.
- Infrastructure being built to support phase two, doubling capacity to 50,000 tons.
- Long-term goal to scale plant to 100,000 tons for battery-grade iron phosphate.
- Total expected capex to reach ~INR 500 crores over next few years.
- Existing pilot plant producing 200 kgs/day; samples supplied to 36+ customers.
- Capacity enhancement planned on existing food grade iron phosphate line to meet early demand before Dahej plant operational.
- Greenfield capex of INR 150 crores for 51,200 MT capacity, with INR 120 crores spent by Sept '25; balance INR 20-30 crores to be spent by March '26.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sudeep Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company anticipates a strong Q3 FY26 due to delayed order book recognition in Q2, especially from the US market impacted by tariff uncertainties.
- NSS, acquired in May 2025, has a significant project pipeline in Europe and global markets to expand its infant and clinical nutrition offerings.
- NSS is currently operating at approximately 35% capacity utilization, with plans to scale up through leveraging Sudeep Pharma’s global customer base.
- Campaign orders for large pharma and nutrition companies contribute significantly but are irregular, causing quarterly fluctuations in order volumes.
2 more points management made on order book & pipeline
Sudeep Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹182 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sudeep Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key concall takeaways from Morepen Laboratories Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key concall takeaways from Anuh Pharma Ltd's Q2 FY26 earnings call — and how it…
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key concall takeaways from Themis Medicare Ltd's Q2 FY26 earnings call…
Frequently Asked Questions
What were Sudeep Pharma Ltd Q2 FY26 results?
FY '26 growth expected at approximately 26%, sustained for the full year. Sudeep Pharma expects to sustain the 26% growth achieved in H1 FY26 for the full year FY26 and beyond, driven by normalization of U.S.
What is Sudeep Pharma Ltd share price analysis?
Sudeep Pharma Ltd currently shows a neutral. The stock trades at a P/E of 59.3 with a market cap of ₹10,831 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sudeep Pharma Ltd planning capital expenditure?
Acquired a 20-acre land in Dahej for new manufacturing facility.
Keep Sudeep Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.